ClinVar Genomic variation as it relates to human health
Help
- Interpretation:
-
drug response
- Review status:
- no assertion criteria provided
- Submissions:
- 1
- First in ClinVar:
- Apr 4, 2013
- Most recent Submission:
- Apr 4, 2013
- Last evaluated:
- May 18, 2015
- Accession:
- VCV000016895.2
- Variation ID:
- 16895
- Description:
- Haplotype
Help
NM_000106.5(CYP2D6):c.[886C>T;457G>C]
- Other names
- CYP2D6, ARG296CYS AND SER486THR
- CYP2D6*2
- Functional consequence
- -
- Links
- ClinGen: CA039192
- OMIM: 124030.0007
This haplotype includes the following variants
Help
Aggregate interpretations per condition
Interpreted condition | Interpretation | Number of submissions | Review status | Last evaluated | Variation/condition record |
---|---|---|---|---|---|
drug response | 1 | no assertion criteria provided | May 18, 2015 | RCV000018391.28 |
Submitted interpretations and evidence
HelpInterpretation (Last evaluated) |
Review status (Assertion criteria) |
Condition (Inheritance) |
Submitter | More information | |
---|---|---|---|---|---|
drug response
(May 18, 2015)
|
no assertion criteria provided
Method: literature only
|
DEBRISOQUINE, ULTRARAPID METABOLISM OF
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000038673.1
First in ClinVar: Apr 04, 2013 Last updated: Apr 04, 2013 |
Comment on evidence:
This allelic variant is also known as CYP2D6*2 or CYP2D6L. In a family in which 2 sibs and their father had MRs of less that … (more)
This allelic variant is also known as CYP2D6*2 or CYP2D6L. In a family in which 2 sibs and their father had MRs of less that 0.02 (ultrarapid phenotype, see 608902), Johansson et al. (1993) found 12 extra copies of the CYP2D6 gene inherited in an autosomal dominant pattern; in a second family in which 2 sibs had MRs of less than 0.1, the authors found 2 extra copies of the CYP2D6 gene. All affected individuals had a variant CYP2D6 gene, termed CYP2D6L, which contained 2 amino acid substitutions: a 2938C-T transition in exon 6, resulting in an arg296-to-cys (R296C), and a 4268G-to-C transversion in exon 9, resulting in a resulting in a ser486-to-thr (S486T) substitution. The MR of individuals with 1 copy of the CYP2D6L gene did not differ from those with the wildtype gene, but there was a correlation between decreased MR and increased copies of the CYP2D6L gene. Panserat et al. (1994) identified the R296C and S486T changes as 2 major CYP2D6 allozymes in extensive metabolizers (wildtype). Residue 296 falls within a presumed substrate recognition site, and residue 486 lies in the vicinity of the heme binding site. (less)
|
Functional evidence
HelpThere is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar. |
Citations for this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers. | Panserat S | Human genetics | 1994 | PMID: 7927337 |
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. | Johansson I | Proceedings of the National Academy of Sciences of the United States of America | 1993 | PMID: 7903454 |
http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=CYP2D6 | - | - | - | - |
Record last updated Aug 11, 2022